Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.
Findings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.
Gilead shares were up almost 2 percent 76.14 prior to the bell.
